Literature DB >> 10996718

Successful immunoglobulin treatment in a patient with neuromyotonia.

G Alessi1, J De Reuck, J De Bleecker, S Vancayzeele.   

Abstract

Neuromyotonia is characterized by spontaneous and continuous muscle fibre activity leading to muscle cramps, pseudomyotonia, myokymia and weakness. Electromyographic recordings show typical findings. An auto-immune mechanism has been suggested in at least a subset of patients. Various therapies have been tried with different outcome. A patient with neuromyotonia responding well to high-dose immunoglobulin treatment is presented.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10996718     DOI： 10.1016/s0303-8467(00)00093-7

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN： 0303-8467            Impact factor:   1.876


  4 in total

Review 1.  [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

2.  Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.

Authors:  Agnes van Sonderen; Paul W Wirtz; Jan J G M Verschuuren; Maarten J Titulaer
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

3.  Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis.

Authors:  Jori Fleisher; Megan Richie; Raymond Price; Steven Scherer; Josep Dalmau; Eric Lancaster
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

Review 4.  The Production Processes and Biological Effects of Intravenous Immunoglobulin.

Authors:  Ana Filipa Barahona Afonso; Cristina Maria Pires João
Journal:  Biomolecules       Date:  2016-03-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.